Principal Securities Inc. Has $231,000 Holdings in Illumina, Inc. (NASDAQ:ILMN)

Principal Securities Inc. lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 38.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,728 shares of the life sciences company’s stock after acquiring an additional 483 shares during the period. Principal Securities Inc.’s holdings in Illumina were worth $231,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. WCM Investment Management LLC boosted its stake in shares of Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after acquiring an additional 867,673 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after acquiring an additional 48,018 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after acquiring an additional 87,599 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after acquiring an additional 625,245 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Illumina by 4.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after acquiring an additional 54,319 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of ILMN stock opened at $94.20 on Monday. The stock has a 50 day moving average of $127.98 and a two-hundred day moving average of $134.22. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12 month low of $93.50 and a 12 month high of $156.66. The company has a market capitalization of $14.92 billion, a P/E ratio of -12.27, a P/E/G ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

ILMN has been the subject of several recent analyst reports. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. UBS Group increased their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada decreased their target price on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group decreased their target price on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. Finally, Stephens increased their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.